Naltrexone aop

Overdose

Capsules; Coated tablet; Pills; SubstanceSubstance-powder

Symptoms

- There is limited clinical experience with Naltrexone AOP overdose in patients.

- There was no evidence of toxicity in volunteers receiving 800 mg/day for seven days.

Treatment

- In case of overdose, patients should be monitored and treated symptomatically in a closely supervised environment.

Symptoms

- There is limited clinical experience with naltrexone overdose in patients.

- There was no evidence of toxicity in volunteers receiving 800 mg/day for seven days.

Treatment

- In case of overdose, patients should be monitored and treated symptomatically in a closely supervised environment.

Contraindications

- Severe renal impairment

- Severe hepatic impairment

- Acute hepatitis

- Opioid addicted patients with a current abuse of opioids since an acute withdrawal syndrome may ensue.

- Positive screening result for opioids or after failure of the naloxone provocation test.

- for use in conjunction with an opioid - containing medication

- in combination with methadone.

Undesirable effects

Capsules; Coated tablet; Pills; SubstanceSubstance-powder

The following undesirable effects are ranked according to system organ class and to their frequency:

Very common (> 1/10)

Common (>1/100 to < 1/10)

Uncommon (>1/1,000 to < 1/100)

Rare (> 1/10,000 to < 1/1,000)

Very rare (< 1/10,000)

not known (cannot be estimated from the available data)

MedDRA system organ class

Infections and infestation

Uncommon

Oral herpes

Tinea pedis

Blood and lymphatic system disorders

Uncommon

Lymphadenopathy

Rare

Idiopathic thrombocytopenic purpura

Metabolism and nutrition disorders

Common

Decreased appetite

Psychiatric disorders:

Very common

Nervousness

Anxiety

Insomnia

Common

Affective disorders

Despondency

Irritability

Mood swings

Uncommon

Hallucination

Confusional state

Depression

Paranoia

Disorientation

Nightmare

Agitation

Libido disorder

Abnormal dreams

Rare

Suicidal ideation

Attempted suicide

Very rare

Euphoria

Nervous system disorder

Very common

Headache

Sleep disorders

Restlessness

Common

Dizziness

Shivering

Vertigo

Uncommon

Tremor

Somnolence

Rare

Speech disorder

Eye disorders

Common

Lacrimation increased

Uncommon

Vision-blurred

Eye irritation

Photophobia

Eye swelling

Eye pain

Asthenopia

Ear and labyrinth disorders

Uncommon

Ear discomfort

Ear pain

Tinnitus

Vertigo

Cardiac disorders

Common

Tachycardia

Palpitations

Electrocardiogram change

Vascular disorders

Uncommon

Blood pressure fluctuation

Flushing

Respiratory, thoracic and mediastinal disorder

Common

Chest pain

Uncommon

Nasal congestion

Nasal discomfort

Rhinorrhea

Sneezing

Oropharyngeal pain

Sputum increased

sinus disorder

Dyspnoea

Dysphonia

Cough

Yawning

Gastrointestinal disorder

Very common

Abdominal pain

Abdominal cramps

Nausea or Inclination to vomit

Vomiting

Common

Diarrhoea

Constipation

Uncommon

Flatulence

Haemorrhoids

Ulcer

Dry mouth

Hepatobiliary disorders

Uncommon

Liver disorder

blood bilirubin increased

hepatitis

During treatment an increase of liver transaminases may occur. After discontinuation of Naltrexone AOP the transaminases decreased to baseline within several weeks.

Skin and subcutaneous tissue disorder

Common

Rash

Uncommon

Seborrhoea

Pruritus

Acne

Alopecia

Very rare

Exanthema

Musculoskeletal and connective tissue disorders :

Very common

Arthralgia

Myalgia

Uncommon

Groin pain

Very Rare

Rhabdomyolysis

Renal and urinary disorders

Common

Urine retention

Uncommon

Pollakiuria

Dysuria

Reproductive system and breast disorders

Common

Delayed ejaculation

Erectile dysfunction

General disorder and administration site conditions

Very common

Feebleness

Asthenia

Common

Lack of appetite

Thirst

Energy increased

Chills

Hyperhidrosis

Uncommon

Increased appetite

weight loss

weight gain

Pyrexia

Pain

Peripheral coldness

Feeling hot

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system (To be completed nationally).

The following undesirable effects are ranked according to system organ class and to their frequency:

Very common (> 1/10)

Common (>1/100 to < 1/10)

Uncommon (>1/1,000 to < 1/100)

Rare (> 1/10,000 to < 1/1,000)

Very rare (< 1/10,000)

not known (cannot be estimated from the available data)

MedDRA system organ class

Infections and infestation

Uncommon

Oral herpes

Tinea pedis

Blood and lymphatic system disorders

Uncommon

Lymphadenopathy

Rare

Idiopathic thrombocytopenic purpura

Metabolism and nutrition disorders

Common

Decreased appetite

Psychiatric disorders:

Very common

Nervousness

Anxiety

Insomnia

Common

Affective disorders

Despondency

Irritability

Mood swings

Uncommon

Hallucination

Confusional state

Depression

Paranoia

Disorientation

Nightmare

Agitation

Libido disorder

Abnormal dreams

Rare

Suicidal ideation

Attempted suicide

Very rare

Euphoria

Nervous system disorder

Very common

Headache

Sleep disorders

Restlessness

Common

Dizziness

Shivering

Vertigo

Uncommon

Tremor

Somnolence

Rare

Speech disorder

Eye disorders

Common

Lacrimation increased

Uncommon

Vision-blurred

Eye irritation

Photophobia

Eye swelling

Eye pain

Asthenopia

Ear and labyrinth disorders

Uncommon

Ear discomfort

Ear pain

Tinnitus

Vertigo

Cardiac disorders

Common

Tachycardia

Palpitations

Electrocardiogram change

Vascular disorders

Uncommon

Blood pressure fluctuation

Flushing

Respiratory, thoracic and mediastinal disorder

Common

Chest pain

Uncommon

Nasal congestion

Nasal discomfort

Rhinorrhea

Sneezing

Oropharyngeal pain

Sputum increased

sinus disorder

Dyspnoea

Dysphonia

Cough

Yawning

Gastrointestinal disorder

Very common

Abdominal pain

Abdominal cramps

Nausea or Inclination to vomit

Vomiting

Common

Diarrhoea

Constipation

Uncommon

Flatulence

Haemorrhoids

Ulcer

Dry mouth

Hepatobiliary disorders

Uncommon

Liver disorder

blood bilirubin increased

hepatitis

During treatment an increase of liver transaminases may occur. After discontinuation of Naltrexone the transaminases decreased to baseline within several weeks.

Skin and subcutaneous tissue disorder

Common

Rash

Uncommon

Seborrhoea

Pruritus

Acne

Alopecia

Very rare

Exanthema

Musculoskeletal and connective tissue disorders :

Very common

Arthralgia

Myalgia

Uncommon

Groin pain

Very Rare

Rhabdomyolysis

Renal and urinary disorders

Common

Urine retention

Uncommon

Pollakiuria

Dysuria

Reproductive system and breast disorders

Common

Delayed ejaculation

Erectile dysfunction

General disorder and administration site conditions

Very common

Feebleness

Asthenia

Common

Lack of appetite

Thirst

Energy increased

Chills

Hyperhidrosis

Uncommon

Increased appetite

weight loss

weight gain

Pyrexia

Pain

Peripheral coldness

Feeling hot

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system (To be completed nationally).

Naltrexone AOP price

We have no data on the cost of the drug.
However, we will provide data for each active ingredient

Preclinical safety data

Capsules; Coated tablet; Pills; SubstanceSubstance-powder

Preclinical data revealed no special hazard for humans based on conventional studies of safety, pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. However, there is some evidence on hepatotoxicity with increasing dose, since reversible increases of liver enzymes has been found in humans with therapeutic and higher doses.

Naltrexone AOP (100 mg/kg, approximately 140 times the human therapeutic dose) caused a significant increase in pseudo-pregnancy in the rat. A decrease in the pregnancy rate of mated female rats also occurred. The relevance of these observations to human fertility is not known.

Naltrexone AOP has been shown to have an embryocidal effect in the rat and rabbit when given in doses approximately 140 times the human therapeutic dose. This effect was demonstrated in rats dosed with 100 mg/kg of Naltrexone AOP prior to and throughout gestation, and rabbits treated with 60 mg/kg of Naltrexone AOP during the period of organogenesis.

Preclinical data revealed no special hazard for humans based on conventional studies of safety, pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. However, there is some evidence on hepatotoxicity with increasing dose, since reversible increases of liver enzymes has been found in humans with therapeutic and higher doses.

Naltrexone (100 mg/kg, approximately 140 times the human therapeutic dose) caused a significant increase in pseudo-pregnancy in the rat. A decrease in the pregnancy rate of mated female rats also occurred. The relevance of these observations to human fertility is not known.

Naltrexone has been shown to have an embryocidal effect in the rat and rabbit when given in doses approximately 140 times the human therapeutic dose. This effect was demonstrated in rats dosed with 100 mg/kg of naltrexone prior to and throughout gestation, and rabbits treated with 60 mg/kg of naltrexone during the period of organogenesis.

Therapeutic indications

For use as an additional therapy within a comprehensive treatment program including psychological guidance for detoxified patients who have been opioid-dependent & alcohol dependence to support abstinence.

Pharmacotherapeutic group

other nervous system drugs; drugs used in addictive disorders, ATC code: N07BB04

Pharmacodynamic properties

Capsules; Coated tablet; Pills; SubstanceSubstance-powder

Pharmacotherapeutic group: other nervous system drugs; drugs used in addictive disorders, ATC code: N07BB04

Naltrexone AOP is a specific opioid antagonist with only minimal agonistic activity. It acts by stereospecific competition with receptors which are mainly located in the central and peripheral nervous system. Naltrexone AOP competitively binds to these receptors and blocks the access for exogenously administered opioids.

Naltrexone AOP treatment does not lead to physical or mental dependence. No tolerance for the opioid antagonising effect is seen.

Naltrexone AOP Hydrochloride 50 mg film-coated tablets reduces the risk of relapse and supports abstinence from opioids.

Naltrexone AOP Hydrochloride 50 mg film-coated tablets is a non-aversive therapy and does not cause reactions after opioid intake. Therefore it does not cause a disulfiram-type reaction.

The mechanism of action of Naltrexone AOP in alcoholism is not completely elucidated, however an interaction with the endogenous opioid system is suspected to play an important role. Alcohol consumption in humans has been hypothesised to be reinforcing through an alcohol-induced stimulation of the endogenous opioid system.

Naltrexone AOP is not an aversive therapy and does not cause a disulfiram-like negative reaction when alcohol is ingested.

The prominent effect of Naltrexone AOP treatment of alcohol-addicted patients seems to be a reduction of the risk of a full relapse with uncontrolled binge-drinking after having consumed a limited amount of alcohol.

This gives the patient a “second chance” to escape the otherwise mutually reinforcing mechanisms of a full relapse with complete loss of control. Naltrexone AOP also seems to have an effect on the primary craving as it is non-reinforcing on isolated consumption of limited amounts of alcohol.

Pharmacotherapeutic group: other nervous system drugs; drugs used in addictive disorders, ATC code: N07BB04

Naltrexone is a specific opioid antagonist with only minimal agonistic activity. It acts by stereospecific competition with receptors which are mainly located in the central and peripheral nervous system. Naltrexone competitively binds to these receptors and blocks the access for exogenously administered opioids.

Naltrexone treatment does not lead to physical or mental dependence. No tolerance for the opioid antagonising effect is seen.

Naltrexone AOP 50 mg film-coated tablets reduces the risk of relapse and supports abstinence from opioids.

Naltrexone AOP 50 mg film-coated tablets is a non-aversive therapy and does not cause reactions after opioid intake. Therefore it does not cause a disulfiram-type reaction.

The mechanism of action of naltrexone in alcoholism is not completely elucidated, however an interaction with the endogenous opioid system is suspected to play an important role. Alcohol consumption in humans has been hypothesised to be reinforcing through an alcohol-induced stimulation of the endogenous opioid system.

Naltrexone is not an aversive therapy and does not cause a disulfiram-like negative reaction when alcohol is ingested.

The prominent effect of naltrexone treatment of alcohol-addicted patients seems to be a reduction of the risk of a full relapse with uncontrolled binge-drinking after having consumed a limited amount of alcohol.

This gives the patient a “second chance” to escape the otherwise mutually reinforcing mechanisms of a full relapse with complete loss of control. Naltrexone also seems to have an effect on the primary craving as it is non-reinforcing on isolated consumption of limited amounts of alcohol.

Pharmacokinetic properties

Capsules; Coated tablet; Pills; SubstanceSubstance-powder

Absorption

Naltrexone AOP is rapidly and almost completely absorbed from the gastrointestinal tract after oral administration.

Biotransformation

It undergoes a liver first-pass effect and peak plasma concentration is reached within approximately one hour.

Naltrexone AOP is hydroxylated in the liver basically to the main active metabolite 6-beta-naltrexol and, to a lesser extent, to 2-hydroxy-3-methoxy-6-beta-naltrexol.

The plasma-half-life of Naltrexone AOP is approximately 4 hours, the average blood level is 8.55 mg/ml, and plasmaprotein-binding is 21%. The plasma-half-life of 6-beta-naltrexol is 13 hours.

Elimination

The medicinal product is excreted primarily renal. About 60% of the peroral dose is excreted within 48 hours as glucuronidised 6-beta-naltrexol and Naltrexone AOP.

Absorption

Naltrexone is rapidly and almost completely absorbed from the gastrointestinal tract after oral administration.

Biotransformation

It undergoes a liver first-pass effect and peak plasma concentration is reached within approximately one hour.

Naltrexone is hydroxylated in the liver basically to the main active metabolite 6-beta-naltrexol and, to a lesser extent, to 2-hydroxy-3-methoxy-6-beta-naltrexol.

The plasma-half-life of naltrexone is approximately 4 hours, the average blood level is 8.55 mg/ml, and plasmaprotein-binding is 21%. The plasma-half-life of 6-beta-naltrexol is 13 hours.

Elimination

The medicinal product is excreted primarily renal. About 60% of the peroral dose is excreted within 48 hours as glucuronidised 6-beta-naltrexol and naltrexone.

Name of the medicinal product

Naltrexone AOP

Qualitative and quantitative composition

Naltrexone Hydrochloride

Special warnings and precautions for use

Capsules; Coated tablet; Pills; SubstanceSubstance-powder

In accordance to national guidance the therapy should be initiated and supervised by a physician experienced in treatment of opioid-addicted and alcohol-addicted patients

High dose opioid intake, concomitant with Naltrexone AOP treatment, can lead to life-threatening opioid poisoning from respiratory and circulatory impairment.

Should Naltrexone AOP be used in opioid-dependent patients a withdrawal syndrome may occur rapidly: the first symptoms can occur within 5 minutes, the last after 48 hours. The treatment of withdrawal symptoms is symptomatic.

It is not uncommon for alcohol abusing individuals to show signs of impaired hepatic function. Abnormal hepatic function test parameters have been reported in obese and elderly patients receiving Naltrexone AOP in dosages higher than recommended (up to 300 mg/day). Hepatic function controls should be made before and during treatment. Special attention should be paid to patients with hepatic enzyme levels in serum exceeding three times the normal value and patients with renal impairment.

Liver function test abnormalities have been reported in obese and elderly patients taking Naltrexone AOP who have no history of drug abuse. Liver function tests should be carried out both before and during treatment.

Patients must be warned against the concomitant use of opioids (e.g. opioids in cough medication, opioids in symptomatic medication for the treatment of common colds, or opioids contained in anti diarrhoeal agents, etc.) during Naltrexone AOP treatment.

Naltrexone AOP treatment must begin only when the opioid has been discontinued for a sufficiently long period (about 5 to 7 days for heroin and at least 10 days for methadone).

If the patient needs opioid treatment, e.g. opioid analgesia or anesthesia in emergency situations, the dose needed may be higher than normal. In these cases, the respiratory depression and circulatory effects will be more profound and longer lasting. Symptoms related to release of histamine (generalized erythema, diaphoresis, itching and other skin and mucocutaneous manifestations) can also be manifested more easily. The patient requires specific attention and care in these situations.

During treatment with Naltrexone AOP, painful conditions should be treated with non-opioid analgesia only.

Patients should be warned that large doses of opioids to overcome the blockade may after the cessation of the Naltrexone AOP result in an acute opioid overdose, with possible fatal outcome.

Patients might be more sensitive to opioid containing medicines after treatment with Naltrexone AOP.

Patients suspected of using or being addicted to opioids must undergo a naloxone provocation test, unless it can be verified that the patient has not taken any opioids for 7-10 days (urine test) prior to the initiation of treatment with Naltrexone AOP.

A withdrawal syndrome precipitated by naloxone will be of shorter duration than withdrawal precipitated by Naltrexone AOP.

The recommended procedure is as follows:

Intravenous provocation

- Intravenous injection of 0.2 mg naloxone

- If after 30 seconds no adverse reactions occur, a further i.v. injection of 0.6 mg naloxone may be administered.

- The patient should be observed continuously for 30 minutes for any detectable sign of withdrawal symptoms.

If any symptoms of withdrawal occur Naltrexone AOP-therapy must not be undertaken. If the test-result is negative the treatment can be initiated. If any doubt exists that the patient is opioid-free, the challenge may be repeated with the dosage of 1.6 mg. If no reaction occurs after this, 25 mg of Naltrexone AOP hydrochloride can be administered to the patient.

A naloxone hydrochloride provocation test should not be made in patients with clinically prominent withdrawal symptoms nor in any case of a positive urine test for opioids.

Naltrexone AOP is extensively metabolised by the liver and excreted predominantly in the urine. Therefore, caution should be observed in administering the medicinal product to patients with impaired hepatic or renal function. Liver function tests should be carried out both before and during treatment.

The risk of suicide is known to increase in substance abusers, with or without concomitant depression. Treatment with Naltrexone AOP tablet does not eliminate this risk.

Lactose

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

In accordance to national guidance the therapy should be initiated and supervised by a physician experienced in treatment of opioid-addicted and alcohol-addicted patients

High dose opioid intake, concomitant with Naltrexone treatment, can lead to life-threatening opioid poisoning from respiratory and circulatory impairment.

Should naltrexone be used in opioid-dependent patients a withdrawal syndrome may occur rapidly: the first symptoms can occur within 5 minutes, the last after 48 hours. The treatment of withdrawal symptoms is symptomatic.

It is not uncommon for alcohol abusing individuals to show signs of impaired hepatic function. Abnormal hepatic function test parameters have been reported in obese and elderly patients receiving naltrexone in dosages higher than recommended (up to 300 mg/day). Hepatic function controls should be made before and during treatment. Special attention should be paid to patients with hepatic enzyme levels in serum exceeding three times the normal value and patients with renal impairment.

Liver function test abnormalities have been reported in obese and elderly patients taking naltrexone who have no history of drug abuse. Liver function tests should be carried out both before and during treatment.

Patients must be warned against the concomitant use of opioids (e.g. opioids in cough medication, opioids in symptomatic medication for the treatment of common colds, or opioids contained in anti diarrhoeal agents, etc.) during naltrexone treatment.

Naltrexone treatment must begin only when the opioid has been discontinued for a sufficiently long period (about 5 to 7 days for heroin and at least 10 days for methadone).

If the patient needs opioid treatment, e.g. opioid analgesia or anesthesia in emergency situations, the dose needed may be higher than normal. In these cases, the respiratory depression and circulatory effects will be more profound and longer lasting. Symptoms related to release of histamine (generalized erythema, diaphoresis, itching and other skin and mucocutaneous manifestations) can also be manifested more easily. The patient requires specific attention and care in these situations.

During treatment with naltrexone, painful conditions should be treated with non-opioid analgesia only.

Patients should be warned that large doses of opioids to overcome the blockade may after the cessation of the naltrexone result in an acute opioid overdose, with possible fatal outcome.

Patients might be more sensitive to opioid containing medicines after treatment with naltrexone.

Patients suspected of using or being addicted to opioids must undergo a naloxone provocation test, unless it can be verified that the patient has not taken any opioids for 7-10 days (urine test) prior to the initiation of treatment with naltrexone.

A withdrawal syndrome precipitated by naloxone will be of shorter duration than withdrawal precipitated by naltrexone.

The recommended procedure is as follows:

Intravenous provocation

- Intravenous injection of 0.2 mg naloxone

- If after 30 seconds no adverse reactions occur, a further i.v. injection of 0.6 mg naloxone may be administered.

- The patient should be observed continuously for 30 minutes for any detectable sign of withdrawal symptoms.

If any symptoms of withdrawal occur naltrexone-therapy must not be undertaken. If the test-result is negative the treatment can be initiated. If any doubt exists that the patient is opioid-free, the challenge may be repeated with the dosage of 1.6 mg. If no reaction occurs after this, 25 mg of Naltrexone AOP can be administered to the patient.

A naloxone hydrochloride provocation test should not be made in patients with clinically prominent withdrawal symptoms nor in any case of a positive urine test for opioids.

Naltrexone is extensively metabolised by the liver and excreted predominantly in the urine. Therefore, caution should be observed in administering the medicinal product to patients with impaired hepatic or renal function. Liver function tests should be carried out both before and during treatment.

The risk of suicide is known to increase in substance abusers, with or without concomitant depression. Treatment with Naltrexone tablet does not eliminate this risk.

Lactose

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Effects on ability to drive and use machines

Capsules; Coated tablet; Pills; SubstanceSubstance-powder

Naltrexone AOP may impair the mental and/or physical abilities required for performance of potentially hazardous tasks such as driving a car or operating machinery.

Naltrexone may impair the mental and/or physical abilities required for performance of potentially hazardous tasks such as driving a car or operating machinery.

Dosage (Posology) and method of administration

Capsules; Coated tablet; Pills; SubstanceSubstance-powder

Use in adults

Naltrexone AOP treatment should be initiated and supervised by suitable qualified physicians.

The initial dose of Naltrexone AOP hydrochloride should be 25 mg (half a tablet) for opioid-dependent patient followed by the usual dose of one tablet per day (= 50 mg Naltrexone AOP hydrochloride)

A missed dose can be managed by providing 1 tablet per day each day till the next regular dosage-administration.

Naltrexone AOP administered to opioid-dependent persons can cause life-threatening withdrawal symptoms. Patients suspected of using or being addicted to opioids must undergo a naloxone provocation test , unless it can be verified that the patient has not taken any opioids for 7-10 days (urine test) prior to the initiation of treatment with Naltrexone AOP.

As Naltrexone AOP is an adjunctive therapy and the full recovery process in opioid-dependent patients is individually variable, no standard duration of treatment can be stated; an initial period of three months should be considered. However, prolonged administration may be necessary.

The recommended dose for alcohol dependence to support abstinence is 50 mg per day (1 tablet). A dose of over 150 mg on any single day is not recommended, since this can lead to a higher incidence of side effects.

As Naltrexone AOP hydrochloride is an adjunctive therapy and the full recovery process from alcohol dependence is individually variable, no standard duration of treatment can be stated; an initial period of three months should be considered. However, prolonged administration may be necessary

The dosage-regimen can be modified in order to improve compliance to a three-times-a-week dosing schedule as follows: administration of 2 tablets (=100 mg Naltrexone AOP hydrochloride) on Monday and on Wednesday and 3 tablets (=150 mg Naltrexone AOP hydrochloride) on Friday.

Paediatric population

Naltrexone AOP should not be used in children and adolescents under 18 years of age, since clinical data in this age-group are lacking. Safe use in children has not been established.

Older people

There are insufficient data on the safety and efficacy of Naltrexone AOP for this indication in elderly patients.

Use in adults

Naltrexone treatment should be initiated and supervised by suitable qualified physicians.

The initial dose of Naltrexone AOP should be 25 mg (half a tablet) for opioid-dependent patient followed by the usual dose of one tablet per day (= 50 mg Naltrexone AOP)

A missed dose can be managed by providing 1 tablet per day each day till the next regular dosage-administration.

Naltrexone administered to opioid-dependent persons can cause life-threatening withdrawal symptoms. Patients suspected of using or being addicted to opioids must undergo a naloxone provocation test , unless it can be verified that the patient has not taken any opioids for 7-10 days (urine test) prior to the initiation of treatment with naltrexone.

As Naltrexone is an adjunctive therapy and the full recovery process in opioid-dependent patients is individually variable, no standard duration of treatment can be stated; an initial period of three months should be considered. However, prolonged administration may be necessary.

The recommended dose for alcohol dependence to support abstinence is 50 mg per day (1 tablet). A dose of over 150 mg on any single day is not recommended, since this can lead to a higher incidence of side effects.

As Naltrexone AOP is an adjunctive therapy and the full recovery process from alcohol dependence is individually variable, no standard duration of treatment can be stated; an initial period of three months should be considered. However, prolonged administration may be necessary

The dosage-regimen can be modified in order to improve compliance to a three-times-a-week dosing schedule as follows: administration of 2 tablets (=100 mg Naltrexone AOP) on Monday and on Wednesday and 3 tablets (=150 mg Naltrexone AOP) on Friday.

Paediatric population

Naltrexone should not be used in children and adolescents under 18 years of age, since clinical data in this age-group are lacking. Safe use in children has not been established.

Older people

There are insufficient data on the safety and efficacy of naltrexone for this indication in elderly patients.

Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.